Abstract
COVID-19 has rapidly become a major concern for the health systems worldwide. Its high contagiousness and associated mortality demand the discovery of helpful interventions with promising safety profile. Here, we report 3 severe COVID-19 cases, which achieved rapid and sustained improvement in outcome with the use of ruxolitinib, a JAK/STAT pathway inhibitor.
References
1.
Schett
G
, Sticherling
M
, Neurath
MF
. COVID-19: risk for cytokine targeting in chronic inflammatory diseases?
Nat Rev Immunol
. 2020
May
;20
(5
):271
–2
.
[PubMed]
1474-17332.
Birndt
S
, Schenk
T
, Heinevetter
B
, Brunkhorst
FM
, Maschmeyer
G
, Rothmann
F
, et al. Hemophagocytic lymphohistiocytosis in adults: collaborative analysis of 137 cases of a nationwide German registry
. J Cancer Res Clin Oncol
. 2020
Apr
;146
(4
):1065
–77
.
[PubMed]
0171-52163.
Zeiser
R
, von Bubnoff
N
, Butler
J
, Mohty
M
, Niederwieser
D
, Or
R
, et al.; REACH2 Trial Group
. Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
. N Engl J Med
. 2020
May
;382
(19
):1800
–10
.
[PubMed]
0028-47934.
Sarmiento Maldonado
M
, Ramírez Villanueva
P
, Bertín Cortes-Monroy
P
, Jara Arias
V
, Soto Donoso
K
, Uribe Gonzalez
P
, et al. Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis
. Exp Hematol Oncol
. 2017
Dec
;6
(1
):32
.
[PubMed]
2162-36195.
Hermans
MA
, Schrijver
B
, van Holten-Neelen
CC
, Gerth van Wijk
R
, van Hagen
PM
, van Daele
PL
, et al. The JAK1/JAK2- inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release
. Clin Exp Allergy
. 2018
Nov
;48
(11
):1412
–20
.
[PubMed]
0954-78946.
Khadka
RH
, Sakemura
R
, Kenderian
SS
, Johnson
AJ
. Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies
. Immunotherapy
. 2019
Jul
;11
(10
):851
–7
.
[PubMed]
1750-743X7.
Wang
J
, Wang
Y
, Wu
L
, Wang
X
, Jin
Z
, Gao
Z
, et al. Ruxolitinib for refractory/relapsed hemophagocytic lymphohistiocytosis
. Haematologica
. 2020
May
;105
(5
):e210
–2
.
[PubMed]
0390-60788.
Elli
EM
, Baratè
C
, Mendicino
F
, Palandri
F
, Palumbo
GA
. Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib
. Front Oncol
. 2019
Nov
;9
:1186
.
[PubMed]
2234-943X9.
Gavegnano
C
, Detorio
M
, Montero
C
, Bosque
A
, Planelles
V
, Schinazi
RF
. Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro
. Antimicrob Agents Chemother
. 2014
;58
(4
):1977
–86
.
[PubMed]
0066-480410.
Kathryn
D
. JAK1 inhibition blocks lethal sterile immune responses: implications for COVID-19 therapy.
bioRxiv
2020.04.07.024455
; doi: 11.
Malard
F
, Genthon
A
, Brissot
E
, van de Wyngaert
Z
, Marjanovic
Z
, Ikhlef
S
, et al. COVID-19 outcomes in patients with hematologic disease
. Bone Marrow Transplant
. 2020
May
;
[PubMed]
0268-336912.
Tefferi
A
, Pardanani
A
. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis
. Mayo Clin Proc
. 2011
Dec
;86
(12
):1188
–91
.
[PubMed]
0025-619613.
Cao
Y
, Wei
J
, Zou
L
, et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial [published online ahead of print, 2020 May 26]. J Allergy Clin Immunol. 2020
;S0091-6749(20)30738-7. doi:14.
La Rosée
F
, Bremer
HC
, Gehrke
I
, Kehr
A
, Hochhaus
A
, Birndt
S
, et al. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation
. [published online ahead of print, 2020 Jun 9]
. Leukemia
. 2020
Jul
;34
(7
):1805
–15
.
[PubMed]
0887-6924© 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.